Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15195819 | 1.00 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL13850026 | 1.00 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6055156 | 0.92 | AOC3 (0.60) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL11616745 | 0.90 | AOC3 (0.59) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6490320 | 0.86 | AOC3 (0.62) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL801059 | 0.86 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3920742 | 0.86 | AOC3 (0.66) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL3920362 | 0.85 | AOC3 (0.60) | AOC3L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL6055198 | 0.85 | MAPK1 (0.50) | AOC3L3MBTL1 | |
| SCHEMBL18293363 | 0.85 | AOC3 (0.65) | AOC3L3MBTL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1847533-B1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2013-08-14 | — | — | EP | disclosed |
| US-7553867-B2 | Furan or thiophene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-30 | — | — | US | disclosed |
| US-7531533-B2 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-05-12 | — | — | US | disclosed |
| EP-1847533-A1 | SIX-MEMBERED HETEROCYCLIC COMPOUND AND THE USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2007-10-24 | — | — | EP | disclosed |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-03-15 | — | — | US | disclosed |
| CN-1297526-C | Asymmetric diether compound and its uses | CHINA PETROLEUM & CHEMICAL (CN) | 2007-01-31 | — | — | CN | disclosed |
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-05-11 | — | — | US | disclosed |
| CN-1769255-A | Asymmetric diether compound and its uses | CHINA PETROLEUM & CHEMICAL (CN) | 2006-05-10 | — | — | CN | disclosed |
| EP-1300381-B1 | Process for preparing optically active alcohols | JAPAN SCIENCE & TECH AGENCY (JP) | 2006-03-08 | — | — | EP | disclosed |
| EP-1535915-A1 | FURAN OR THIOPHENE DERIVATIVE AND MEDICINAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-6887820-B1 | For producing optically active secondary alcohols, producing optically active compounds useful for various utilities such as intermediates for synthesizing pharmaceutical agents, liquid crystal materials and agents for optical resolution | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-05-03 | — | — | US | disclosed |
| EP-1300381-A1 | Process for preparing optically active alcohols | Japan Science and Technology Corporation (JP) | 2003-04-09 | — | — | EP | disclosed |
| US-6184381-B1 | USEFUL AS INTERMEDIATES FOR SYNTHESIZING PHARMACEUTICAL CHEMICALS, LIQUID CRYSTAL MATERIALS AND AGENTS FOR OPTICAL RESOLUTION, REDUCTION, KETONES TO ALCOHOL, IMINES TO AMINES | JAPAN SCIENCE & TECHNOLOGY CORP. (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0916637-A1 | PROCESS FOR PREPARATING OPTICALLY ACTIVE COMPOUNDS | Japan Science and Technology Corporation (JP) | 1999-05-19 | — | — | EP | disclosed |
| US-4094994-A | ANTICANCER AGENTS, TUMOR INHIBITION, HORMONE-DEPENDENT CARCINOMAS | KLINGE PHARMA GMBH (DT) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100261-A1 | Furan or thiopene derivative and medicinal use thereof | TXN2, CYP11B2, CYP11B1 | AOC3 455/4885L3MBTL1 1515/4885CHRM2 13/4885 |
| US-20070060590-A1 | 6-Membered heterocyclic compound and use thereof | WNT1, CYP11B2, CYP11B1 | AOC3 1100/4885L3MBTL1 1886/4885CHRM2 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.